Study of Dabigatran Use in a Brazilian Public Hospital Specialized in
            Cardiology

Martins, Luise Barros; Martins, Ivis Levy Fernandes; Silva, Raíssa Miranda; Almeida, Flávia Valéria dos Santos; Scaramello, Christianne Brêtas Vieira

doi:10.5935/2359-4802.20170052

International Journal of Cardiovascular Sciences

2017

DOI: 10.5935/2359-4802.20170052

|View full text |Cite

Study of Dabigatran Use in a Brazilian Public Hospital Specialized in Cardiology

Luise Barros Martins

Ivis Levy Fernandes Martins

Raíssa Miranda Silva

et al.

Abstract: Background: During its commercialization phase, unprecedented effects of new medicaments can be discovered. Dabigatran is an anticoagulant approved by Brazilian National Health Surveillance Agency in 2008.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Publication Types

Select...

Relationship

Self Cite0

Independent0

Authors

Journals

Cited by 0 publications

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

No citations

Set email alert for when this publication receives citations?

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

334 Leonard St

Brooklyn, NY 11211

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Study of Dabigatran Use in a Brazilian Public Hospital Specialized in Cardiology

Abstract: Background: During its commercialization phase, unprecedented effects of new medicaments can be discovered. Dabigatran is an anticoagulant approved by Brazilian National Health Surveillance Agency in 2008.

Cited by 0 publications

References 29 publications

No citations

Contact Info

Product

Resources

About